Biofrontera Inc
$ 0.94
-6.03%
05 Jun - close price
- Market Cap 11,971,100 USD
- Current Price $ 0.94
- High / Low $ 1.00 / 0.92
- Stock P/E N/A
- Book Value 0.52
- EPS -0.98
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -3.39 %
- 52 Week High 1.19
- 52 Week Low 0.56
About
Biofrontera Inc., a biopharmaceutical company, develops and supplies dermatological products for the treatment of skin conditions in the United States. The company is headquartered in Woburn, Massachusetts.
Analyst Target Price
$5.88
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-19 | 2025-11-12 | 2025-08-13 | 2025-05-15 | 2025-03-21 | 2024-11-13 | 2024-08-14 | 2024-05-15 | 2024-03-15 | 2023-11-09 | 2023-08-11 |
| Reported EPS | -0.41 | 0.5 | -0.57 | -0.57 | -0.51 | -0.232 | -0.81 | -1.08 | -2.88 | -0.68 | -3.16 | -6.07 |
| Estimated EPS | -0.05 | 0.1 | -0.56 | -0.39 | -0.29 | -0.07 | -0.94 | -0.35 | -1.17 | -0.85 | -3.34 | -4.08 |
| Surprise | -0.36 | 0.4 | -0.01 | -0.18 | -0.22 | -0.162 | 0.13 | -0.73 | -1.71 | 0.17 | 0.18 | -1.99 |
| Surprise Percentage | -720% | 400% | -1.7857% | -46.1538% | -75.8621% | -231.4286% | 13.8298% | -208.5714% | -146.1538% | 20% | 5.3892% | -48.7745% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.04 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BFRI
2026-05-31 21:39:46
Biofrontera Inc. (Nasdaq:BFRI) is a biopharmaceutical company focused on dermatological treatments, with a market capitalization of US$12.4 million. The company is currently unprofitable but analysts forecast significant earnings growth for future years. Recent developments include Q1 2026 earnings, regulatory milestones for its Ameluz product, and ongoing clinical trials for various dermatological conditions, but also highlights risks like its small market cap and negative cash flow.
2026-05-31 06:39:45
This article provides financial information for Biofrontera Inc. (NASDAQ:BFRIW) on TradingView. It appears to be a financial data page rather than a traditional article, showing stock market data and offering various financial tools and community features. The primary focus is on the number of shareholders for the specified company.
2026-05-29 22:09:59
Biofrontera AG reported its results for Q1 2026, showing significant improvements including a 13.8% increase in European sales revenues and positive EBITDA from continued operations. The company's total result increased by 225% to EUR 2,200 thousand, primarily driven by improved results from discontinued US operations. Biofrontera confirmed its 2026 fiscal year forecast, focusing on portfolio expansion in Europe after stabilizing its financial position and reducing risks associated with the US market.
2026-05-29 19:40:36
This article provides a detailed overview of BIOFRONTERA INC (NASDAQ:BFRI) stock, including its current price, performance statistics over various periods, key financial data, and analyst forecasts. It highlights BFRI's fundamental and technical ratings from ChartMill, its recent earnings report which missed EPS and revenue expectations, and upcoming earnings date. The report also covers ownership details, industry overview, and recent news related to the company.
2026-05-28 16:39:21
Biofrontera Inc. (BFRI) is experiencing strong year-over-year revenue growth and improved gross margins, supported by a robust dermatology product pipeline. The company plans key regulatory submissions in 2026 to expand indications and market share, aiming for a path to break-even. This information was based on an AI-generated summary of Biofrontera Inc.'s Lytham Partners Spring 2026 Investor Conference Audio Transcript.
2026-05-21 16:39:03
Biofrontera Inc. will participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026. The biopharmaceutical company will host a webcast presentation at 11:00 a.m. ET and conduct virtual one-on-one meetings with investors throughout the event. Biofrontera specializes in photodynamic therapy for dermatological conditions, commercializing Ameluz® for Actinic Keratosis.
